Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS Major milestone will provide IP protection in key European markets, strengthening global patent portfolio
Poolbeg Pharma PLC (AIM: POLB) Preclinical data posters presented at EHA Congress
Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress
Poolbeg Pharma (AIM: POLB) Pre-IND Meeting with the FDA for POLB 001
FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions
POLB 001 poster to be presented at EHA 2026 Congress
Poolbeg Pharma plc is set to present new data on its drug candidate POLB 001 at the upcoming European Hematology Association Congress 2026, highlighting the treatment’s potential to prevent cancer
POLB 001 cancer immunotherapy-induced CRS patent granted in Canada
Further strengthening of Poolbeg’s global intellectual property portfolio
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma is stepping up partnering discussions with multiple pharma groups
Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.
Poolbeg Pharma CEO speaks on BioHub podcast in London
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma receives UK clearance to begin cancer immunotherapy trial
Poolbeg Pharma plc (AIM: POLB) has received Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency for its POLB 001 TOPICAL trial, marking a key regulatory milestone
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma (AIM: POLB) Significant milestone for Poolbeg’s IP portfolio
Grant of first POLB 001 cancer immunotherapy-induced CRS patent Significant milestone for Poolbeg’s global intellectual property portfolio